Properties of Stereodefined Variants of Nusinersen
Open Access
- 13 November 2026
- journal article
- Published by SAGE Publications in Nucleic Acid Therapeutics
Abstract
In the pharmaceutical industry, stereopure drugs are generally preferred over isomeric mixtures to reduce the risks of side effects and to simplify pharmacodynamics (PD) and pharmacokinetics (PK) properties. This reasoning applies equally to antisense oligonucleotides (ASOs). All current ASO drugs are modified to provide appropriate PK/PD properties. Among the modifications, phosphorothioate (PS) groups provide essential nuclease resistance and advantageous biodistribution properties. However, PS groups are chiral, with R p- and S p-centers that are challenging to incorporate stereoselectively during solid-phase synthesis, and thus current ASO drugs are diastereoisomeric mixtures. Here, we describe the synthesis of stereodefined variants of the approved drug nusinersen (Spinraza), a 2′- O -methoxyethyl-modified oligonucleotide that redirects splicing of SMN2 during treatment for spinal muscular atrophy (SMA). We found that a single 3′- S p linkage stabilizes nusinersen from degradation in mouse tissue homogenates. Although R p-nusinersen has higher target-binding affinity than S p-nusinersen, it is not more active than parent nusinersen in patient-derived cells. Finally, we show mixed results from comparing stereodefined nusinersen with parent nusinersen in a murine model of SMA. While our data do not provide definitive evidence for the superior performance of stereodefined nusinersen, we conclude that it is likely equally effective as its parent ASO, while bearing the pharmacological advantages of a single stereoisomer.Funding Information
- National Institutes of Health (F30CA281196)
- National Institutes of Health (GM42699)
- National Institutes of Health (T32- GM008444)
- National Center of Competence in Research RNA and Disease
- St. Giles Foundation
This publication has 52 references indexed in Scilit:
- In vitro metabolism of 2′‐ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometryBiomedical Chromatography, 2020
- Characterization of therapeutic oligonucleotides by liquid chromatographyJournal of Pharmaceutical and Biomedical Analysis, 2020
- Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass SpectrometryMolecular Therapy Nucleic Acids, 2019
- Chromatographic methods for the determination of therapeutic oligonucleotidesJournal of Chromatography B, 2012
- Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophyBiochemical and Biophysical Research Communications, 2010
- Modification of HER2 pre‐mRNA alternative splicing and its effects on breast cancer cellsInternational Journal of Cancer, 2008
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic MiceThe American Journal of Human Genetics, 2008
- Tissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in MonkeysJournal of Pharmaceutical Sciences, 2004
- Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren OligonucleotideHelvetica Chimica Acta, 1995
- Identification and characterization of a spinal muscular atrophy-determining geneCell, 1995